7.31 USD
▼-0.44-5.68%
盘后 7.00 0.00%
2026-09-16
市值
$50.79M
市盈率
—
EPS
-6.32
股息率
—
52 周区间
3.64 – 43.66
成交量
2.45K
Beta
0.19
目标价
—
52W 低 3.6452W 高 43.66
价格走势
公司简介
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID pr...